PMID- 38492515
OWN - NLM
STAT- MEDLINE
DCOM- 20240408
LR  - 20240408
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 125
DP  - 2024 Apr
TI  - How to deal with renal toxicities from immune-based combination treatments in 
      metastatic renal cell carcinoma. A nephrological consultation for Oncologists.
PG  - 102692
LID - S0305-7372(24)00010-0 [pii]
LID - 10.1016/j.ctrv.2024.102692 [doi]
AB  - We are witnessing a revolution in the treatment of metastatic renal cell 
      carcinoma (mRCC). Indeed, several immune-based combinations (ICI [immune 
      checkpoint inhibitor] + ICI, or ICI + antiangiogenic agents) have been approved 
      as first-line therapy for mRCC after demonstrating superior efficacy over the 
      previous standard. Despite all the improvements made, safety remains a critical 
      issue, adverse events (AEs) being the main reason for drug discontinuations or 
      dose reductions, ultimately resulting in an increased risk of losing efficacy. 
      Thus, a good understanding of the AEs associated with the use of immune-based 
      combinations, their prevention, and management, are key in order to maximize 
      therapeutic effectiveness. Among these AEs, renal ones are relatively frequent, 
      but always difficult to be diagnosed, not to take into account that it is often 
      difficult to determine which drug is to blame for such toxicities. Chronic kidney 
      disease (CKD) is a common finding in patients with RCC, either as a pre-existing 
      condition and/or as a consequence of cancer and its treatment; furthermore, CKD, 
      especially in advanced stages and in patients undergoing dialysis, may influence 
      the pharmacokinetics and pharmacodynamics properties of anticancer agents. 
      Finally, managing cancer therapy in kidney transplanted patients is another 
      challenge. In this review, we discuss the therapy management of immune-based 
      combinations in patients with CKD, on dialysis, or transplanted, as well as their 
      renal toxicities, with a focus on their prevention, detection and practical 
      management, taking into account the crucial role of the consulting nephrologist 
      within the multidisciplinary care of these patients.
CI  - Copyright (c) 2024. Published by Elsevier Ltd.
FAU - Marcello, Tucci
AU  - Marcello T
AD  - Division of Medical Oncology, "Cardinal Massaia" Hospital, Asti, Italy.
FAU - Laura, Cosmai
AU  - Laura C
AD  - Onconephrology Outpatient Clinic, ASST Fatebenefratelli-Sacco, Milan, Italy; 
      Division of Nephrology and Dialysis, ASST Fatebenefratelli-Sacco, Milan, Italy. 
      Electronic address: lacos@iol.it.
FAU - Marta, Pirovano
AU  - Marta P
AD  - Onconephrology Outpatient Clinic, ASST Fatebenefratelli-Sacco, Milan, Italy; 
      Division of Nephrology and Dialysis, ASST Fatebenefratelli-Sacco, Milan, Italy.
FAU - Ilaria, Campisi
AU  - Ilaria C
AD  - Department of Oncology, University of Turin, Turin, Italy. Electronic address: 
      ilaria.campisi723@edu.unito.it.
FAU - Sarto Giulia Vanessa, Re
AU  - Sarto Giulia Vanessa R
AD  - Onconephrology Outpatient Clinic, ASST Fatebenefratelli-Sacco, Milan, Italy; 
      Division of Nephrology and Dialysis, ASST Fatebenefratelli-Sacco, Milan, Italy. 
      Electronic address: giulia.resarto@unimi.it.
FAU - Camillo, Porta
AU  - Camillo P
AD  - Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, 
      Italy; Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, 
      Bari, Italy. Electronic address: camillo.porta@uniba.it.
FAU - Maurizio, Gallieni
AU  - Maurizio G
AD  - Division of Nephrology and Dialysis, ASST Fatebenefratelli-Sacco, Milan, Italy; 
      Department of Biomedical and Clinical Sciences, University of Milan, Milan, 
      Italy. Electronic address: maurizio.gallieni@unimi.it.
FAU - Messa, Piergiorgio
AU  - Messa P
AD  - Division of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca' 
      Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Clinical 
      Sciences and Community Health, University of Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240123
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/pathology
MH  - *Kidney Neoplasms/pathology
MH  - *Renal Insufficiency, Chronic
MH  - Referral and Consultation
MH  - *Oncologists
OTO - NOTNLM
OT  - Diagnosis
OT  - Immune-based combinations
OT  - Renal adverse events
OT  - Renal cell carcinoma
OT  - Therapy management
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/17 00:42
MHDA- 2024/04/08 06:43
CRDT- 2024/03/16 19:11
PHST- 2023/11/03 00:00 [received]
PHST- 2024/01/09 00:00 [revised]
PHST- 2024/01/22 00:00 [accepted]
PHST- 2024/04/08 06:43 [medline]
PHST- 2024/03/17 00:42 [pubmed]
PHST- 2024/03/16 19:11 [entrez]
AID - S0305-7372(24)00010-0 [pii]
AID - 10.1016/j.ctrv.2024.102692 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2024 Apr;125:102692. doi: 10.1016/j.ctrv.2024.102692. Epub 2024 
      Jan 23.